SEC Form 5

FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0362							
Estimated average burden								
hours per response:	1.0							

Form 3 Holdings Reported.

Instruction 1(b)

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Form 4 Transact	tions Reported.	File			e Securities Exchange Act of 1934 ment Company Act of 1940	ļ							
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Mehta Vimal</u>				<u>nerupeuu</u>		X	Director	10	% Owner				
(Last)	(First)	(Middle)	3. Statement fo	or Issuer's Fisc	al Year Ended (Month/Day/Year)	x	Officer (give tit below)		her (specify low)				
C/O BIOXCEL THERAPEUTICS, INC.,			12/31/2021			CEO and President							
555 LONG WH	ARF DRIVE												
(Street)			4. If Amendme	nt, Date of Ori	ginal Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)							
1 · /	СТ	06511				X	Form filed by C	One Reporting	Person				
			-				Form filed by More than One Reporting Person						
(City)	(State)	(Zip)					1 613011						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
			2A. Deemed Execution Date,	3. Transaction	4. Securities Acquired (A) or Dispo Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities	6. Ownership	7. Nature of Indirect				

(Month/Day/Year) if any (Month/Day/Year) Code (Instr. Beneficially Form: Direct Beneficial 8) Owned at end of (D) or Ownership lssuer's Fiscal Ìndirect (I) (Instr. 4) (A) or (D) Amount Price Year (Instr. 3 and (Instr. 4) 4) See 102,568(1) Common Stock 04/06/2021 G D \$<mark>0</mark> 8,546,750 I Footnote⁽¹⁾ See Common Stock 04/06/2021 G 130,659(2) D \$<mark>0</mark> 8,546,750 I Footnote⁽²⁾ See Common Stock 04/06/2021 G 130,659(3) A \$<mark>0</mark> 8,546,750 I Footnote⁽³⁾ See Common Stock 04/06/2021 G 102,568(4) D \$<mark>0</mark> 8,546,750 Ι Footnote⁽⁴⁾ Common Stock 2,000 Ι By spouse Common Stock 9.957 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	nversion Date E Exercise (Month/Day/Year) if ce of rivative	3A. Deemed Execution Date, if any (Month/Day/Year)	of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
										(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

2. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

3. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse received by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

4. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

<u>/s/ Javier Rodriguez, as</u> <u>Attorney in Fact for Vimal</u> 02/14/2022 <u>Mehta</u> ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.